Importantly, the results also suggest that proteasome activators that amplify and unmask the tumor immunopeptidome may dictate the efficacy of T-cell immunotherapy, in contrast to other proposed mechanisms, e.g., PD-L1/PD-L2 expression, TMB, and microsatellite instability. Here, PDCD1LG2 is linked to neoplasm.